Recursion Pharmaceuticals

Home
United States
Salt Lake City, UT
Recursion Pharmaceuticals

Recursion is a clinical stage TechBio company decoding biology to industrialize drug discovery and radically improve lives.

Traditional drug discovery methods are inefficient and expensive – approximately 90% of all drugs in clinical trials ultimately fail to get approved and the total investment needed to develop each approved medicine exceeds $2 billion. This inefficiency occurs because biology is extraordinarily complex, and our industry has historically lacked the tools to understand how it functions. At Recursion, we’re harnessing the convergence of multiple breakthrough technologies that allow our scientists to explore uncharted areas of biology and unravel its complexity to navigate the path to better treatments. We have built a massive proprietary biological and chemical database that predicts trillions of relationships across biology and chemistry, many of which are not known in scientific literature. Our approach generates novel insights, broadens the scope of potential medicines, and truly industrializes drug discovery – increasing the scale, speed and efficiency of each step of the process. We believe our technology and approach has the potential to not only radically improve the lives of patients, but also change the landscape of drug discovery and development forever.

11/18/2025

In a new video, Communications and Culture Fellow Katherine Matsumoto asks Recursionauts: “What is one thing you wish your families understood about the work that you do?”

For many, it’s all about the patients.

11/17/2025

🎉 Incoming CEO Najat Khan was named one of 2025’s Fiercest Women in Life Sciences from Fierce Pharma.🎉

Each year, the list celebrates women who are making a powerful impact across biopharma and medtech, and have strong track records in innovation, leadership, and mentorship.

Najat has always found ways to break down barriers in her career – from integrating data science at scale at Johnson & Johnson Innovative Medicine to leading the acceleration of the Recursion OS 2.0 into a true end-to-end AI-enabled platform for drug discovery and development. She’s seen firsthand the benefit of merging life sciences and technology disciplines in her own life and is a true believer that the future of medicine lies in this intersection.

“By bringing together AI, biology, chemistry, and clinical science, together with business acumen,” Najat says, “I believe we can fundamentally change how medicines are discovered and developed and deliver innovation that truly changes patients’ lives.”

👉 Read more: https://www.fiercepharma.com/pharma/2025s-fiercest-women-life-sciences

11/13/2025

We’re headed to the Jefferies Global Healthcare Conference & London Life Sciences Week!

Just added - we’re now partnering on a BoltzGen Presentation on Nov. 19, 5-9pm at Recursion’s London office in King’s Cross. Get the latest details on the new BoltzGen model and discuss the future of biomolecular design. Register here (in-person only): https://luma.com/l2zgvfwt

Full events list:

Mon., Nov 17, 11:50am: Future of Life Sciences panel: “AI in Life Sciences: Is It All Hype?” from Knowledge Quarter. At London Life Sciences Week Pavilion. https://
lifesciencesweek.london

Tues., Nov. 18, 10:30am: Jefferies Global Healthcare Conference Fireside Chat. Webcast: https://wsw.com/webcast/jeff332/register.aspx?conf=jeff332&page=rxrx&url=https%3A//wsw.com/webcast/jeff332/rxrx/1900764

Tues., Nov. 18, 3:30pm: London Bio Afternoon Tea with BACKED VC. https://
gatsby.events/backed-vc/rsvp
/register?e=london-bio-london-life-sciences-week-jefferies-2025&ref=speaker

Wed., Nov. 19, 5:00pm: BoltzGen Presentation in partnership with Recursion. https://luma.com/l2zgvfwt

Thurs., Nov 20, 6pm: London Life Sciences Week Knowledge Quarter Closing Event at One Triton Square. https://luma.com/lifesciencewrapparty

See you there!

Learn more: https://
londonandpartners.com/newsroom/news-
and-communications/london-surges-ahead-as-europes-life-sciences-capital

11/12/2025

🔹 Presenting REC-102: Preclinical in vivo updates for a potential ENPP1 inhibitor for the treatment of hypophosphatasia (HPP).

On Sept. 6, Recursion collaborators in the lab of José Luis Millán, PhD, Professor of the Human Genetics Program at Sanford Children’s Health Research Center, presented a poster on REC-102, Recursion’s oral ENPP1 inhibitor for HPP, a rare genetic disease that causes skeletal and dental hypomineralization at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting. Results of the study – investigating whether inhibiting the enzyme ENPP1 could offer an alternative to current injection-based therapies – have been published in the Journal of Bone and Mineral Research.

REC-102 leveraged AI-enabled precision design capabilities from our platform to optimize for compound properties suitable for chronic dosing, enabling a candidate with potential best-in-class characteristics.

💡 Key takeaways from early preclinical data include:

▪️ Novel Therapeutic Strategy

▪️ Encouraging PPi Reduction In Vivo

▪️ Improved Bone Mineralization

👉 Read the paper: https://academic.oup.com/jbmr/advance-article/doi/10.1093/jbmr/zjaf136/8275834

11/06/2025

🚀 Recursion announced a leadership transition plan to drive the next phase of its growth.

Effective January 1st, Chris Gibson, Co-Founder and CEO, will transition to Chairman of the Board, Najat Khan, PhD, Chief R&D and Commercial Officer, will be named CEO and President and Robert Hershberg, Recursion’s current Chairman, will transition to Vice-Chairman and Lead Independent Director.

11/04/2025

Recursion announced today that it will participate in the following upcoming investor conferences:

▪️ Nov. 11, 8 am ET: Guggenheim Securities 2nd Annual Healthcare Innovation Conference in Boston

▪️ Nov. 18, 10:30 am GMT: Jefferies Global Healthcare Conference in London

👉 Tune in to the webcasts at: ir.recursion.com.

11/03/2025

The making of the world’s first Microglia Map to explore new targets for neurological diseases.

In our latest Explain the Impact video, we share the inside story of the first-of-its-kind Microglia Map from Recursion and Roche and Genentech – including the development of new cell manufacturing techniques to produce over 100 billion microglial cells – and why the field has struggled for so long to expand neuroscience therapies beyond a few well-known targets even though neurological conditions are the #1 cause of illness and disability worldwide.

10/31/2025

👩‍🔬 A new round of Returnship opportunities are now available!

Recursion’s 16-week Returnship Program gives those who have taken a hiatus (2+ years) from the STEM industry the opportunity to return to the workforce, providing hands-on experience on cutting edge tools and technology, along with mentorship and weekly seminars.

🧪 New Returnship roles are now available in: Tissue Culture, Biology Multi-Omics Assay Development; CMC Analysis; CMC Financial; Data Science and Product Management.

Interested? Explore our open Returnship roles here: https://job-boards.greenhouse.io/recursionpharmaceuticals

10/30/2025

In case you missed it – our (L)earnings Call will be held on Wednesday, November 5.

Learn more about our just-announced Microglia Map with Roche and Genentech along with other business updates and third quarter 2025 financial results on Wednesday, November 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT.

We will broadcast the (L)earnings Call livestream on:
▪️ YouTube: https://youtube.com/
▪️ LinkedIn: https://www.linkedin.com/company/recursion-pharmaceuticals/
▪️X: https://x.com/recursionpharma

👉 Submit questions for the (L)earnings Call here: https://forms.gle/TQ4vgUTLKsFmikcu6
👉 Read more: https://ir.recursion.com/news-releases/news-release-details/recursion-report-third-quarter-2025-business-updates-and/

10/28/2025

The third episode of our TechBio Talks podcast is now live, featuring leading AI investor Nathan Benaich of Air Street Capital in conversation with host Chris Gibson, cofounder and CEO of Recursion.

They talk about the evolving landscape of AI in drug discovery, the biggest trends identified in Nathan’s new State of AI Report, and what AI investors are looking for, now and in the future.

Check it out:

Tracking investment trends in TechBio. The third episode of the TechBio Talks podcast features host Chris Gibson in conversation with leading AI investor Nat...

10/27/2025

If you’re working in AI, you most likely saw the just-released 2025 State of AI Report from Nathan Benaich, Founder and General Partner at . The annual report is a must-read deep dive into the state of the industry, with this year’s highlights including: reasoning going mainstream; AI models becoming active co-scientists; and serious commercial traction, with 44% of US businesses now paying for AI tools.

Tomorrow, get the behind-the-scenes story on the report and much more in a new episode of TechBio Talks, featuring Nathan in conversation with Chris Gibson.

In it, Nathan shares what it means to be an “AI-first investor” and how his approach has evolved over time with the rapid acceleration of technology.

As he says in the clip, he’s interested in companies where “The AI is the product.”

🎙️ Subscribe to TechBio Talks on:
▪️ Spotify: https://open.spotify.com/show/2bjoBPssiZVmjYKG4AlaW4
▪️ YouTube: https://www.youtube.com/playlist?list=PLpz4Z2GmPXlYlTfOAcVtsTgfRIn1XKwHL
▪️ Apple: https://podcasts.apple.com/us/podcast/techbio-talks/id1834770803

10/21/2025

Nowhere will the acceleration of the UK’s TechBio sector be more evident than the upcoming London Life Sciences Week (Nov. 16-21). Centered around the Jefferies
European Healthcare Conference, it brings together the global investor community and UK life sciences industry for a week of networking, deal-making, and collaboration.

Recursion executives will present at a number of events including:

Mon., Nov 17, 11:50am: Future of Life Sciences panel: “AI in Life Sciences: Is It All Hype?” with Najat Khan, PhD, Chief R&D Officer and Chief Commercial Officer at Recursion; Laura Acqualagna, Director of AI/ML Engineering at
; Manish Gupta, Chairman and CEO, .official; and chaired by Jodie Eastwood, CEO, . https://
lifesciencesweek.london

Tues., Nov. 18, 10:30am: Jefferies Global Healthcare Conference Fireside Chat with Chris Gibson, Najat Khan, and Ben Taylor

Tues., Nov. 18, 3:30pm: London Bio Afternoon Tea with
featuring Chris Gibson and Sir Jonathan Symonds, CBE, Chair of GSK. https://
gatsby.events/backed-vc/rsvp
/register?e=london-bio-london-life-sciences-week-jefferies-2025&ref=speaker

Thurs., Nov 20, 6pm: London Life Sciences Week Knowledge Quarter Closing Event at One Triton Square. https://
luma.com/lifesciencewra
pparty

See you there!

Address

41 S Rio Grande Street
Salt Lake City, UT
84108

Website

http://www.recursion.com/

Alerts

Be the first to know and let us send you an email when Recursion Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Recursion Pharmaceuticals:

Shortcuts

Want your practice to be the top-listed Clinic in Salt Lake City?

Our Story

Our dynamic team combines innovative biological science with advanced computational algorithms to discover new therapeutic opportunities for rare genetic diseases. We use high-throughput genetic manipulation to model many diseases in multiple human cell types quickly and efficiently. Thousands of cells representing each model are imaged using high-throughput automated microscopy. We use automated image segmentation systems to quantify hundreds or thousands of structural relationships in tens of thousands of cells for every disease we model. Our proprietary informatics approaches enable us to identify the critical disease-specific changes associated with each disease model. Once we have quantified the phenotypic fingerprint (phenoprint) for a disease, we model it en-masse in thousands of wells and evaluate the ability of thousands of drugs to rescue the disease-specific structural perturbations back to 'health'.